+-----------------------+-----------------------+-----------------------+
| ## Licensee           | **Product**           | **FDA Approval Date   |
|                       |                       | /\                    |
|                       |                       | First Commercial U.S. |
|                       |                       | Sale**                |
+=======================+=======================+=======================+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Berlex Laboratories   | Fludara^®^            | 18 April 1991 / 1991  |
+-----------------------+-----------------------+-----------------------+
| -   A DNA polymerase  |                       |                       |
|     inhibitor         |                       |                       |
|     (fludarabine)     |                       |                       |
|     that has been     |                       |                       |
|     shown to have     |                       |                       |
|     potent activity   |                       |                       |
|     in the treatment  |                       |                       |
|     of B-cell         |                       |                       |
|     leukemia. This    |                       |                       |
|     compound is a     |                       |                       |
|     cancer            |                       |                       |
|     chemotherapeutic  |                       |                       |
|     drug, 2-F-araA.   |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Bristol Myers Squibb  | Videx^®^              | 09 Oct 1991 / 1991    |
+-----------------------+-----------------------+-----------------------+
| -   A treatment of    |                       |                       |
|     HIV infection     |                       |                       |
|     with ddI.         |                       |                       |
|     Selectively       |                       |                       |
|     inhibits the      |                       |                       |
|     replication of    |                       |                       |
|     HIV by            |                       |                       |
|     interfering with  |                       |                       |
|     a critical        |                       |                       |
|     element known as  |                       |                       |
|     reverse           |                       |                       |
|     transcriptase.    |                       |                       |
|     Because of being  |                       |                       |
|     better tolerated  |                       |                       |
|     or having a       |                       |                       |
|     different pattern |                       |                       |
|     of toxicity than  |                       |                       |
|     other treatments, |                       |                       |
|     patients may find |                       |                       |
|     it useful in      |                       |                       |
|     either individual |                       |                       |
|     or combination    |                       |                       |
|     treatment         |                       |                       |
|     therapy.          |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Hoffmann LaRoche      | Hivid^®^              | 19 Jun 1992 / 1992    |
+-----------------------+-----------------------+-----------------------+
| -   A treatment of    |                       |                       |
|     HIV infection     |                       |                       |
|     with ddC.         |                       |                       |
|     Inhibits the      |                       |                       |
|     replication of    |                       |                       |
|     HIV by            |                       |                       |
|     interfering with  |                       |                       |
|     the critical      |                       |                       |
|     enzyme reverse    |                       |                       |
|     transcriptase.    |                       |                       |
|     Patients find it  |                       |                       |
|     useful in either  |                       |                       |
|     individual or     |                       |                       |
|     combination       |                       |                       |
|     treatment         |                       |                       |
|     therapy.          |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Bristol Myers Squibb  | Taxol^®^              | 29 Dec 1992 / 1996    |
+-----------------------+-----------------------+-----------------------+
| -   An improved       |                       |                       |
|     method for        |                       |                       |
|     administering     |                       |                       |
|     Taxol^®^          |                       |                       |
|     (paclitaxel) has  |                       |                       |
|     significantly     |                       |                       |
|     improved the      |                       |                       |
|     treatment of      |                       |                       |
|     cancerous tumors, |                       |                       |
|     particularly      |                       |                       |
|     advanced stage    |                       |                       |
|     epithelial        |                       |                       |
|     ovarian and       |                       |                       |
|     breast cancers.   |                       |                       |
|     Paclitaxel is a   |                       |                       |
|     compound derived  |                       |                       |
|     from the bark of  |                       |                       |
|     the Western Yew   |                       |                       |
|     tree.             |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| MedImmune Inc.        | NeuTrexin^®^          | 17 Dec 1993 / 1994    |
+-----------------------+-----------------------+-----------------------+
| -   A treatment using |                       |                       |
|     trimetrexate as   |                       |                       |
|     an anti-parasitic |                       |                       |
|     agent for         |                       |                       |
|     infection.        |                       |                       |
|     Infections due to |                       |                       |
|     Toxoplasma gondii |                       |                       |
|     and Pneumocystis  |                       |                       |
|     carinii, as seen  |                       |                       |
|     in AIDS patients  |                       |                       |
|     are extremely     |                       |                       |
|     refractory to     |                       |                       |
|     standard therapy  |                       |                       |
|     can be            |                       |                       |
|     effectively       |                       |                       |
|     treated by        |                       |                       |
|     administering     |                       |                       |
|     this drug.        |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| GlaxoSmithKline       | Havrix^®^             | 22 Feb 1995 / 1997    |
+-----------------------+-----------------------+-----------------------+
| -   A vaccine from    |                       |                       |
|     the isolation of  |                       |                       |
|     Hepatitis A virus |                       |                       |
|     strain HM-175.    |                       |                       |
|     Hepatitis A is    |                       |                       |
|     probably the most |                       |                       |
|     widespread of     |                       |                       |
|     viral hepatitis   |                       |                       |
|     diseases and is   |                       |                       |
|     an endemic        |                       |                       |
|     childhood disease |                       |                       |
|     in the            |                       |                       |
|     underdeveloped    |                       |                       |
|     countries of the  |                       |                       |
|     world.            |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Janssen               | SPORANOX^®^ Oral      | 21 Feb 1997 / 1997    |
| Pharmaceuticals       | Solution              |                       |
+-----------------------+-----------------------+-----------------------+
| -   Oral formulation  |                       |                       |
|     of the            |                       |                       |
|     anti-fungal agent |                       |                       |
|     itraconazole that |                       |                       |
|     is used for the   |                       |                       |
|     treatment of      |                       |                       |
|     painful and       |                       |                       |
|     debilitating      |                       |                       |
|     fungal infections |                       |                       |
|     of the esophagus  |                       |                       |
|     and mouth,        |                       |                       |
|     commonly called   |                       |                       |
|     thrush.           |                       |                       |
|     Itraconazole is   |                       |                       |
|     solubilized for   |                       |                       |
|     this application  |                       |                       |
|     through coupling  |                       |                       |
|     with              |                       |                       |
|     hydroxy           |                       |                       |
| -propyl-cyclodextrin, |                       |                       |
|     a molecular       |                       |                       |
|     inclusion         |                       |                       |
|     complex.          |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Protein Design        | ZENAPAX^®^            | 10 Dec 1997 / 1998    |
| Laboratory / Hoffman  |                       |                       |
| LaRoche               |                       |                       |
+-----------------------+-----------------------+-----------------------+
| -   A humanized       |                       |                       |
|     monoclonal        |                       |                       |
|     antibody used for |                       |                       |
|     the prevention of |                       |                       |
|     acute kidney      |                       |                       |
|     transplant        |                       |                       |
|     rejection. This   |                       |                       |
|     recombinantly     |                       |                       |
|     produced antibody |                       |                       |
|     achieves its      |                       |                       |
|     immunosuppressive |                       |                       |
|     properties by     |                       |                       |
|     binding to the    |                       |                       |
|     alpha (or Tac)    |                       |                       |
|     subunit of human  |                       |                       |
|     interleukin-2     |                       |                       |
|     (IL-2) receptor   |                       |                       |
|     that is expressed |                       |                       |
|     on the surface of |                       |                       |
|     activated         |                       |                       |
|     lymphocytes.      |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| MedImmune Inc.        | Synagis^®^            | 19 Jun 1998 / 1998    |
+-----------------------+-----------------------+-----------------------+
| -   A monoclonal      |                       |                       |
|     antibody used for |                       |                       |
|     the prevention    |                       |                       |
|     and treatment of  |                       |                       |
|     serious lower     |                       |                       |
|     respiratory tract |                       |                       |
|     disease by        |                       |                       |
|     respiratory       |                       |                       |
|     syncytial virus   |                       |                       |
|     (RSV). RSV is the |                       |                       |
|     most common cause |                       |                       |
|     of pneumonia and  |                       |                       |
|     bronchiolitis in  |                       |                       |
|     infancy and early |                       |                       |
|     childhood.        |                       |                       |
|     Synagis is the    |                       |                       |
|     world's first     |                       |                       |
|     monoclonal        |                       |                       |
|     antibody licensed |                       |                       |
|     by the FDA for    |                       |                       |
|     any infectious    |                       |                       |
|     disease.          |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Baxter                | Certiva™              | 29 Jul 1998 / 1998    |
| Pharmaceuticals,      |                       |                       |
| formerly North        |                       |                       |
| American Vaccine,     |                       |                       |
| Inc.                  |                       |                       |
+-----------------------+-----------------------+-----------------------+
| -   A combined        |                       |                       |
|     diphtheria,       |                       |                       |
|     tetanus and       |                       |                       |
|     acellular         |                       |                       |
|     pertussis vaccine |                       |                       |
|     for use in        |                       |                       |
|     infants and       |                       |                       |
|     children. A       |                       |                       |
|     special process   |                       |                       |
|     that reduces      |                       |                       |
|     local and         |                       |                       |
|     systemic adverse  |                       |                       |
|     events commonly   |                       |                       |
|     associated with   |                       |                       |
|     traditional       |                       |                       |
|     whole-cell DPT    |                       |                       |
|     vaccine           |                       |                       |
|     administration    |                       |                       |
|     has detoxified    |                       |                       |
|     the acellular     |                       |                       |
|     pertussis         |                       |                       |
|     component of this |                       |                       |
|     vaccine. Certiva™ |                       |                       |
|     is the first      |                       |                       |
|     pediatric vaccine |                       |                       |
|     introduced into   |                       |                       |
|     the U.S. market   |                       |                       |
|     by a new          |                       |                       |
|     independent       |                       |                       |
|     vaccine producer  |                       |                       |
|     in over ten       |                       |                       |
|     years.            |                       |                       |
|     (Manufacturer has |                       |                       |
|     withdrawn the     |                       |                       |
|     product from the  |                       |                       |
|     market)           |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Isis Pharmaceuticals  | Vitravene^®^          | 26 Aug 1998 / 1998    |
| Inc.                  |                       |                       |
+-----------------------+-----------------------+-----------------------+
| -   A                 |                       |                       |
|     phosphorothioate  |                       |                       |
|     oligonucleotide   |                       |                       |
|     that inhibits     |                       |                       |
|                       |                       |                       |
|  cytomeglovirus (CMV) |                       |                       |
|     infections in the |                       |                       |
|     eye. Such         |                       |                       |
|     infections        |                       |                       |
|     commonly occur in |                       |                       |
|     immunocompromised |                       |                       |
|     patients with     |                       |                       |
|     resultant damage  |                       |                       |
|     to the retina.    |                       |                       |
|     Vitravene^®^ is   |                       |                       |
|     the first         |                       |                       |
|     antisense         |                       |                       |
|     therapeutic       |                       |                       |
|     approved for use  |                       |                       |
|     in humans.        |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Wyeth Laboratories    | RotaShield^®^         | 31 Aug 1998 / 1998    |
| Inc.                  |                       |                       |
+-----------------------+-----------------------+-----------------------+
| -   A live oral       |                       |                       |
|     vaccine for the   |                       |                       |
|     prevention of     |                       |                       |
|     rotavirus         |                       |                       |
|     gastroenteritis   |                       |                       |
|     in infants.       |                       |                       |
|     Rotavirus is the  |                       |                       |
|     single most       |                       |                       |
|     common cause of   |                       |                       |
|     epidemic severe   |                       |                       |
|     acute             |                       |                       |
|     gastroenteritis   |                       |                       |
|     (diarrhea and     |                       |                       |
|     vomiting) in      |                       |                       |
|     infants and       |                       |                       |
|     children from     |                       |                       |
|     both developed    |                       |                       |
|     and developing    |                       |                       |
|     countries.        |                       |                       |
|     RotoShield^®^ is  |                       |                       |
|     the first         |                       |                       |
|     rotavirus vaccine |                       |                       |
|     approved for use  |                       |                       |
|     in humans.        |                       |                       |
|     (Manufacturer has |                       |                       |
|     withdrawn the     |                       |                       |
|     product from the  |                       |                       |
|     market)           |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Berlex Laboratories,  | AcuTect^®^            | 14 Sep 1998 / 1998    |
| formerly Diatide Inc. |                       |                       |
+-----------------------+-----------------------+-----------------------+
| -   A synthetic       |                       |                       |
|     peptide           |                       |                       |
|                       |                       |                       |
|   radiopharmaceutical |                       |                       |
|     used for the      |                       |                       |
|     detection of      |                       |                       |
|     acute deep venous |                       |                       |
|     thrombosis (DVT). |                       |                       |
|     DVT affects an    |                       |                       |
|     estimated 5       |                       |                       |
|     million           |                       |                       |
|     individuals in    |                       |                       |
|     the U.S. each     |                       |                       |
|     year and is the   |                       |                       |
|     most common       |                       |                       |
|     source of         |                       |                       |
|     pulmonary         |                       |                       |
|     embolism.         |                       |                       |
|     AcuTect^®^ is the |                       |                       |
|     first in-vivo     |                       |                       |
|     imaging agent to  |                       |                       |
|     target acute DVT  |                       |                       |
|     in the lower      |                       |                       |
|     extremities.      |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Genzyme Corp.         | Thyrogen^®^           | 30 Nov 1998 / 1998    |
+-----------------------+-----------------------+-----------------------+
| -   A recombinant     |                       |                       |
|     form of human     |                       |                       |
|     thyroid           |                       |                       |
|     stimulating       |                       |                       |
|     hormone (TSH) for |                       |                       |
|     use in follow-up  |                       |                       |
|     screening of      |                       |                       |
|     patients who have |                       |                       |
|     been treated for  |                       |                       |
|     thyroid cancer.   |                       |                       |
|     Thyrogen^®^       |                       |                       |
|     permits these     |                       |                       |
|     patients to avoid |                       |                       |
|     the debilitating  |                       |                       |
|     effects of        |                       |                       |
|     thyroid hormone   |                       |                       |
|     withdrawal while  |                       |                       |
|     undergoing        |                       |                       |
|     standard          |                       |                       |
|     diagnostic        |                       |                       |
|     procedures such   |                       |                       |
|     as serum          |                       |                       |
|     thyroglobulin     |                       |                       |
|     testing and       |                       |                       |
|     radioiodine       |                       |                       |
|     imaging.          |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| GlaxoSmithKline       | LYMErix™              | 21 Dec 1998 / 1999    |
+-----------------------+-----------------------+-----------------------+
| -   The world's first |                       |                       |
|     vaccine for the   |                       |                       |
|     prevention of     |                       |                       |
|     Lyme disease.     |                       |                       |
|     Lyme disease is   |                       |                       |
|     one of the        |                       |                       |
|     fastest           |                       |                       |
|     vector-borne      |                       |                       |
|     diseases in the   |                       |                       |
|     US. It can lead   |                       |                       |
|     to severe and     |                       |                       |
|     debilitating      |                       |                       |
|     problems such as  |                       |                       |
|     arthritis, heart  |                       |                       |
|     abnormalities and |                       |                       |
|     Bell's palsy.     |                       |                       |
|     (Manufacturer has |                       |                       |
|     withdrawn the     |                       |                       |
|     product from the  |                       |                       |
|     market)           |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Berlex Laboratories,  | NeoTect^®^            | 03 Aug 1999 / 1999    |
| formerly Diatide Inc. |                       |                       |
+-----------------------+-----------------------+-----------------------+
| -   A synthetic       |                       |                       |
|     peptide           |                       |                       |
|                       |                       |                       |
|   radiopharmaceutical |                       |                       |
|     used for the      |                       |                       |
|     diagnosis of lung |                       |                       |
|     cancer. The probe |                       |                       |
|     binds to          |                       |                       |
|     somatostatin      |                       |                       |
|     receptor-bearing  |                       |                       |
|     masses in the     |                       |                       |
|     lungs, and offers |                       |                       |
|     additional        |                       |                       |
|     information to    |                       |                       |
|     the physician.    |                       |                       |
|     The procedure,    |                       |                       |
|     being minimally   |                       |                       |
|     invasive, carries |                       |                       |
|     much reduced risk |                       |                       |
|     compared to       |                       |                       |
|     invasive          |                       |                       |
|     procedures like   |                       |                       |
|     biopsies.         |                       |                       |
|     (Manufacturer has |                       |                       |
|     withdrawn the     |                       |                       |
|     product from the  |                       |                       |
|     market)           |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| MedImmune Inc./\      | Parvovirus B19 Enzyme | 06 Aug 1999 / 2001    |
| Biotrin International | Immunoassay           |                       |
+-----------------------+-----------------------+-----------------------+
| -   By detecting B19  |                       |                       |
|     virus IgM         |                       |                       |
|     antibodies in     |                       |                       |
|     human serum and   |                       |                       |
|     plasma, this      |                       |                       |
|     product should be |                       |                       |
|     helpful in        |                       |                       |
|     diagnosing and    |                       |                       |
|     managing          |                       |                       |
|     parvovirus B19    |                       |                       |
|     infection, which  |                       |                       |
|     can put pregnant  |                       |                       |
|     women at serious  |                       |                       |
|     risk of fetal     |                       |                       |
|     loss. This is the |                       |                       |
|     first diagnostic  |                       |                       |
|     test for          |                       |                       |
|     parvovirus B19    |                       |                       |
|     infection         |                       |                       |
|     approved by the   |                       |                       |
|     FDA for U.S. use. |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| GlaxoSmithKline       | Twinrix^®^            | 11 May 2001 / 2001    |
+-----------------------+-----------------------+-----------------------+
| -   A vaccine         |                       |                       |
|     formulation that  |                       |                       |
|     combines both     |                       |                       |
|     Hepatitis A and   |                       |                       |
|     Hepatitis B.      |                       |                       |
|     Combining the two |                       |                       |
|     vaccines, for two |                       |                       |
|     of the most       |                       |                       |
|     common infectious |                       |                       |
|     diseases that     |                       |                       |
|     represent serious |                       |                       |
|     public health     |                       |                       |
|     problems,         |                       |                       |
|     Twinrix^®^ offers |                       |                       |
|     significant       |                       |                       |
|     advantages such   |                       |                       |
|     as increased      |                       |                       |
|     convenience for   |                       |                       |
|     patient and       |                       |                       |
|     physician, fewer  |                       |                       |
|     injections and    |                       |                       |
|     greater           |                       |                       |
|     compliance        |                       |                       |
|     compared with two |                       |                       |
|     separate          |                       |                       |
|     vaccines.         |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| IDEC Pharmaceuticals  | Zevalin^®^            | 19 Feb 2002 / 2002    |
+-----------------------+-----------------------+-----------------------+
| -   A treatment for   |                       |                       |
|     non-Hodgkin's     |                       |                       |
|     lymphoma, which   |                       |                       |
|     affects 50,000    |                       |                       |
|     Americans         |                       |                       |
|     annually. A       |                       |                       |
|     majority of these |                       |                       |
|     cases are         |                       |                       |
|     low-grade         |                       |                       |
|     lymphomas that do |                       |                       |
|     not respond to    |                       |                       |
|     other treatments. |                       |                       |
|     Treatment with    |                       |                       |
|     Zevalin^®^, which |                       |                       |
|     is simple and     |                       |                       |
|     fast, and has     |                       |                       |
|     less severe side  |                       |                       |
|     effects, is       |                       |                       |
|     especially suited |                       |                       |
|     for these         |                       |                       |
|     patients. This    |                       |                       |
|     drug combines the |                       |                       |
|     targeting power   |                       |                       |
|     of monoclonal     |                       |                       |
|     antibodies with   |                       |                       |
|     the cell killing  |                       |                       |
|     ability of        |                       |                       |
|     radioactive       |                       |                       |
|     atoms, and is the |                       |                       |
|     first             |                       |                       |
|                       |                       |                       |
|    radioimmunotherapy |                       |                       |
|     to be approved by |                       |                       |
|     the FDA.          |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Millennium            | Velcade^®^            | 13 May 2003 / 2003    |
| Pharmaceuticals       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| -   A treatment for   |                       |                       |
|     multiple myeloma, |                       |                       |
|     that works by     |                       |                       |
|     specifically      |                       |                       |
|     inhibiting an     |                       |                       |
|     enzyme complex    |                       |                       |
|     known as the      |                       |                       |
|     proteosome. Under |                       |                       |
|     an accelerated    |                       |                       |
|     approval program, |                       |                       |
|     the FDA has       |                       |                       |
|     allowed the use   |                       |                       |
|     of Velcade in     |                       |                       |
|     patients who have |                       |                       |
|     failed two prior  |                       |                       |
|     therapies. The    |                       |                       |
|     selectivity and   |                       |                       |
|     manageable        |                       |                       |
|     side-effect       |                       |                       |
|     profile of this   |                       |                       |
|     boronic dipeptide |                       |                       |
|     compound makes it |                       |                       |
|     an exciting new   |                       |                       |
|     cancer drug. NIH  |                       |                       |
|     researchers made  |                       |                       |
|     a critical        |                       |                       |
|     contribution by   |                       |                       |
|     developing        |                       |                       |
|     stable,           |                       |                       |
|     pharmaceutically  |                       |                       |
|     acceptable        |                       |                       |
|     compositions of   |                       |                       |
|     these important   |                       |                       |
|     compounds.        |                       |                       |
|     Indeed, as the    |                       |                       |
|     first proteosome  |                       |                       |
|     inhibitor to be   |                       |                       |
|     approved by the   |                       |                       |
|     FDA, Velcade^®^   |                       |                       |
|     opens the door    |                       |                       |
|     for a new class   |                       |                       |
|     of useful drugs.  |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Angiotech/Boston      | TAXUS™ Express^2™^    | 04 Mar 2004 / 2004    |
| Scientific            | Monorail              |                       |
|                       | Paclitaxel-Eluting    |                       |
|                       | Coronary Stent System |                       |
+-----------------------+-----------------------+-----------------------+
| -   Treatment of      |                       |                       |
|     coronary artery   |                       |                       |
|     disease by        |                       |                       |
|     balloon           |                       |                       |
|     angioplasty and   |                       |                       |
|     placement of a    |                       |                       |
|     stent is often    |                       |                       |
|     followed by       |                       |                       |
|     restenosis caused |                       |                       |
|     by cellular       |                       |                       |
|     proliferation.    |                       |                       |
|     The TAXUS™        |                       |                       |
|     Express^2^™ stent |                       |                       |
|     system contains   |                       |                       |
|     two medical       |                       |                       |
|     components: the   |                       |                       |
|     Express^2^        |                       |                       |
|     coronary stent    |                       |                       |
|     and paclitaxel    |                       |                       |
|     contained in a    |                       |                       |
|     polymer coating.  |                       |                       |
|     NIH researchers   |                       |                       |
|     discovered that   |                       |                       |
|     the paclitaxel    |                       |                       |
|     component         |                       |                       |
|     inhibits cellular |                       |                       |
|     proliferation and |                       |                       |
|     subsequent        |                       |                       |
|     restenosis thus   |                       |                       |
|     leading to        |                       |                       |
|     greatly improved  |                       |                       |
|     medical outcomes. |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Barr Laboratories     | Didanosine            | 03 Dec 2004 /         |
|                       | Delayed-Release       |                       |
|                       | Capsules              |                       |
+-----------------------+-----------------------+-----------------------+
| -   Generic           |                       |                       |
|     equivalent for    |                       |                       |
|     Videx^®^ EC, a    |                       |                       |
|     treatment of HIV  |                       |                       |
|     infection with    |                       |                       |
|     ddI. Selectively  |                       |                       |
|     inhibits the      |                       |                       |
|     replication of    |                       |                       |
|     HIV by            |                       |                       |
|     interfering with  |                       |                       |
|     a critical        |                       |                       |
|     element known as  |                       |                       |
|     reverse           |                       |                       |
|     transcriptase.    |                       |                       |
|     Because of being  |                       |                       |
|     better tolerated  |                       |                       |
|     or having a       |                       |                       |
|     different pattern |                       |                       |
|     of toxicity than  |                       |                       |
|     other treatments, |                       |                       |
|     patients may find |                       |                       |
|     it useful in      |                       |                       |
|     either individual |                       |                       |
|     or combination    |                       |                       |
|     treatment         |                       |                       |
|     therapy.          |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
| Amgen Inc.            | Kepivance™            | 15 Dec 2004 /         |
+-----------------------+-----------------------+-----------------------+
| -   Kepivance™        |                       |                       |
|     (palifermin) is a |                       |                       |
|     human             |                       |                       |
|     keratinocyte      |                       |                       |
|     growth factor     |                       |                       |
|     protein produced  |                       |                       |
|     using recombinant |                       |                       |
|     DNA technology.   |                       |                       |
|     It is used to     |                       |                       |
|     decrease the      |                       |                       |
|     incidence and     |                       |                       |
|     duration of       |                       |                       |
|     severe mouth      |                       |                       |
|     sores in patients |                       |                       |
|     with hematologic  |                       |                       |
|     cancers who       |                       |                       |
|     receive           |                       |                       |
|     myelotoxic        |                       |                       |
|     therapy.  In such |                       |                       |
|     a therapy, the    |                       |                       |
|     patients\'        |                       |                       |
|     myeloid cells are |                       |                       |
|     first destroyed   |                       |                       |
|     by chemotherapy   |                       |                       |
|     alone or in       |                       |                       |
|     combination with  |                       |                       |
|     radiation, and    |                       |                       |
|     then              |                       |                       |
|     reconstituted     |                       |                       |
|     with a bone       |                       |                       |
|     marrow            |                       |                       |
|     transplant.       |                       |                       |
|     Kepivance™ is the |                       |                       |
|     first and only    |                       |                       |
|     therapy to treat  |                       |                       |
|     the severe mouth  |                       |                       |
|     sores that        |                       |                       |
|     afflict these     |                       |                       |
|     patients as a     |                       |                       |
|     painful and       |                       |                       |
|     unavoidable side  |                       |                       |
|     effect of the     |                       |                       |
|     treatment.        |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+
|                       |                       |                       |
+-----------------------+-----------------------+-----------------------+